Back to top
more

Evoke Pharma (EVOK)

(Delayed Data from NSDQ)

$0.44 USD

0.44
15,641

-0.01 (-2.57%)

Updated Apr 25, 2024 03:43 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (159 out of 251)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Evoke Pharma, Inc. (EVOK) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Evoke Pharma, Inc. (EVOK) delivered earnings and revenue surprises of -125.00% and -98.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Evoke Pharma (EVOK) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Evoke Pharma (EVOK) stock based on the movements in the options market lately.

New Strong Sell Stocks for August 24th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance

by Zacks Equity Research

The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.

Foamix Initiates Phase II Study on Acne Combination Foam

by Zacks Equity Research

Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

Zynerba Releases Data on Epilepsy Candidate, Stock Down

by Zacks Equity Research

Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.

Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.

Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs

by Zacks Equity Research

Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.

Generic-Drugs Stock Outlook: No Respite from Pricing Issues

by Zacks Equity Research

Generic drugmakers, in general, are having a rather poor year, primarily due to ongoing pricing pressure and rising competition.

    Ekta Bagri headshot

    Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead

    by Ekta Bagri

    Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.

      Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA

      by Zacks Equity Research

      The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.

        Falling Earnings Estimates Signal Weakness Ahead for Amphastar (AMPH)

        by Zacks Equity Research

        Amphastar (AMPH) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.

          Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III

          by Zacks Equity Research

          Pharma, Inc. (EVOK) announced additional data from a phase III trial on Gimoti (nasal delivery), a novel formulation of its marketed drug, metoclopramide, for diabetic gastroparesis in adult women.

            Company News for December 19, 2016

            by Zacks Equity Research

            Companies in the News are: NFLX,AMZN,EGLT,EVOK,JBL

              3 Healthcare Stocks Poised to Beat Q2 Earnings

              by Zacks Equity Research

              in the second quarter, results have managed to outpace expectations so far.